| Old Articles: <Older 4951-4960 Newer> |
|---|
 |
The Motley Fool
July 2, 2008
Rich Smith |
American Science & Wow! American Science & Engineering, maker of high-tech X-ray machines, announces one of the biggest contracts it's ever reported.   |
The Motley Fool
July 1, 2008
Brian Lawler |
FDA News Gives Glaxo a Glimmer of Hope Approval is delayed, but new studies won't be needed for Cervarix. |
The Motley Fool
July 1, 2008
Brian Orelli |
As the FDA Generics Office Turns The FDA reluctantly gives Teva a 180-day exclusive period to sell generic Risperdal. |
Chemistry World
July 2008
William Bains |
Beyond shareholder returns The author offers a new model for the pharmaceutical industry |
Chemistry World
July 2008
Derek Lowe |
Column: In the pipeline This is not a good time to be an ordinary, interchangeable scientist in the drug industry, because the ordinary scientists are usually the first ones to be shown the door. |
The Motley Fool
June 30, 2008
Brian Orelli |
Johnson & Johnson Grows Up a Little Its Concerta for attention-deficit disorder is approved for use in adults. |
The Motley Fool
June 30, 2008
Brian Orelli |
A Drug to End Merck's Headache? Merck presents promising data for its phase 3 migraine drug. |
The Motley Fool
June 30, 2008
Brian Orelli |
Merck and Schering Get Half a Divorce The lovey-dovey duo ends their respiratory partnership. |
The Motley Fool
June 28, 2008
Rick Aristotle Munarriz |
A Fool Looks Back Smartphones, smart buys, and smarting drug makers filled Wall Street this past week. |
The Motley Fool
June 27, 2008
Brian Lawler |
Difficult Obstacles for SciClone With all the new technologies and discoveries, some drugmakers are undoubtedly going to be left in the dust. SciClone Pharmaceuticals, with its lead drug Zadaxin, might be one such drugmaker. |
| <Older 4951-4960 Newer> Return to current articles. |
